✦ LIBER ✦

Sleep in restless legs syndrome improves during opioid treatment – Results from a large 1-year multi-center trial

✍ Scribed by Benes, H.; Trenkwalder, C.; Garcia-Borreguero, D.; Bosse, B.; Hopp, M.; Kohnen, R.

Book ID: 122106311
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 36 KB
Volume: 14
Category: Article
ISSN: 1389-9457
DOI: 10.1016/j.sleep.2013.11.145

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

No augmentation during opioid treatment

No augmentation during opioid treatment in restless legs syndrome – Results from a 1 year long-term trial

✍ Kohnen, R.; Bosse, B.; Hopp, M.; Winkelmann, J.; Allen, R.; Trenkwalder, C. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 35 KB

Cabergoline compared to levodopa in the

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial

✍ Claudia Trenkwalder; Heike Benes; Ludger Grote; Svenja Happe; Birgit Högl; Johan 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

## Abstract We report the first large‐scale double‐blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily dos

Progressive development of augmentation

Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study

✍ Birgit Högl; Diego García-Borreguero; Ralf Kohnen; Luigi Ferini-Strambi; Georgio 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 262 KB

Efficacy and safety of pramipexole in ch

Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: Results from a multi-center, randomized, double-blind, placebo-controlled trial

✍ Jian-Fang Ma; Qi Wan; Xin-Yue Hu; Sheng-Gang Sun; Wei-Zhi Wang; Zhong-Xin Zhao; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Results from a 1-year, open-label, singl

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

✍ Nolte, F.; HÃ¶chsmann, B.; Giagounidis, A.; LÃ¼bbert, M.; Platzbecker, U.; Haase 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 215 KB